rift
valley
fever
zoonot
arthropodborn
diseas
affect
livestock
human
etiolog
agent
rift
valley
fever
viru
rvfv
bunyavirida
phleboviru
primarili
transmit
mosquito
bite
also
transmit
exposur
infecti
aerosol
present
licens
vaccin
therapeut
prevent
treat
sever
rvfv
infect
human
previous
report
activ
favipiravir
vaccin
strain
rvfv
bunyavirus
cell
cultur
addit
efficaci
also
document
mous
hamster
model
infect
relat
punta
toro
viru
challeng
hamster
highli
pathogen
strain
rvfv
evalu
activ
favipiravir
lethal
infect
subcutan
rvfv
challeng
result
substanti
serum
tissu
viral
load
caus
sever
diseas
mortal
within
day
infect
oral
favipiravir
mgkgday
prevent
mortal
greater
hamster
challeng
rvfv
administ
within
h
postexposur
reduc
rvfv
titer
serum
tissu
rel
time
treatment
initi
contrast
although
ribavirin
mgkgday
effect
protect
anim
peracut
rvfv
diseas
ultim
succumb
delayedonset
neurolog
diseas
associ
high
rvfv
burden
brain
observ
moribund
anim
combin
ribavirin
treatment
start
h
postinfect
significantli
improv
surviv
outcom
reduc
serum
tissu
viru
titer
compar
monotherapi
find
demonstr
signific
postrvfv
exposur
efficaci
favipiravir
peracut
diseas
delayedonset
neuroinvas
suggest
ad
benefit
combin
ribavirin
rift
valley
fever
viru
rvfv
genu
phleboviru
famili
bunyavirida
signific
human
veterinari
pathogen
rvf
zoonot
arthropodborn
diseas
caus
acut
febril
ill
human
livestock
speci
signific
morbid
mortal
associ
sever
manifest
diseas
coupl
current
absenc
licens
therapeut
vaccin
prevent
treat
sever
rvfv
infect
human
underlin
need
develop
antivir
therapi
ribavirin
broad
spectrum
antivir
act
purin
nucleosid
analog
activ
sever
bunyavir
infect
includ
rvfv
ergonul
peter
et
al
princip
mechan
action
clear
evid
suggest
direct
polymeras
inhibit
rna
cap
interfer
lethal
mutagenesi
indirect
inosin
monophosph
dehydrogenas
inhibit
immunomodulatori
effect
mechan
may
role
ribavirin
antivir
effect
graci
cameron
leyssen
et
al
howev
due
concern
doserel
hemolyt
anemia
possibl
teratogen
effect
ribavirin
approv
compassion
use
investig
new
drug
protocol
borio
et
al
snell
favipiravir
promis
pyrazin
deriv
demonstr
potent
antivir
activ
multipl
rna
virus
intracellular
host
enzym
act
upon
convert
activ
form
naesen
et
al
function
purin
nucleotid
analog
select
inhibit
rnadepend
rna
polymeras
rdrp
influenza
viru
furuta
et
al
jin
et
al
sangawa
et
al
demonstr
weaker
inhibit
inosin
monophosph
dehydrogenas
ribavirin
unlik
ribavirin
interfer
dna
rna
synthesi
specif
like
contribut
low
toxic
compound
present
clinic
develop
influenza
inhibitor
japan
new
drug
applic
file
unit
state
phase
clinic
trial
demonstr
robust
activ
vaccin
strain
rvfv
cell
cultur
gowen
et
al
gowen
et
al
addit
antivir
activ
vitro
sever
relat
bunyavirus
sever
hantavirus
la
cross
viru
punta
toro
sandfli
fever
phlebovirus
report
buy
et
al
gowen
et
al
safronetz
et
al
punta
toro
viru
ptv
access
less
biohazard
agent
biosafeti
level
belong
genu
rvfv
use
model
sever
rvfv
infect
differ
anim
model
anderson
et
al
fisher
et
al
pifat
smith
consequ
initi
studi
evalu
efficaci
ptv
infect
model
gowen
et
al
gowen
et
al
base
promis
result
demonstr
inhibit
ptv
infect
establish
rodent
model
vitro
activ
compound
strain
rvfv
current
studi
investig
efficaci
pathogen
rvfv
infect
golden
syrian
hamster
rvfv
strain
obtain
dr
stuart
nichol
cdc
atlanta
ga
viru
stock
passag
cell
passag
vero
cell
deriv
clarifi
cell
cultur
lysat
titrat
concentr
plaqueform
unit
pfu
ml
african
green
monkey
kidney
cell
line
vero
purchas
american
type
cultur
collect
atcc
manassa
va
maintain
minim
essenti
medium
mem
supplement
heatinactiv
fetal
bovin
serum
fb
thermo
fisher
scientif
hyclon
logan
ut
vitro
antivir
assay
serum
reduc
fb
gentamicin
sigmaaldrich
st
loui
mo
ad
medium
final
concentr
provid
toyama
chemic
compani
ltd
toyama
japan
ribavirin
icn
pharmaceut
inc
costa
mesa
ca
vivo
studi
compound
dissolv
carboxymethylcellulos
cmc
sigmaaldrich
st
loui
mo
prior
administr
cell
cultur
test
ribavirin
dissolv
mem
contain
gentamicin
rvfv
titrat
vero
cell
confluent
plate
micropl
cultur
medium
contain
fb
cell
cultur
infecti
dose
ccid
produc
maxim
cytopath
effect
cpe
day
halflog
dilut
ribavirin
ad
triplic
test
well
time
infect
highest
test
compound
concentr
start
toxic
determin
drug
ad
absenc
viru
infect
plate
incub
co
virusinfect
control
well
observ
cpe
day
neutral
red
nr
assay
measur
cell
viabil
perform
previous
describ
kumaki
et
al
briefli
supernat
remov
viru
yield
reduct
vyr
assay
infect
cell
control
subsequ
stain
nr
solut
h
co
incub
nr
solut
remov
well
rins
phosphatebuff
salin
pb
incorpor
dye
extract
use
ethanol
buffer
sorenson
citrat
buffer
plate
read
primari
refer
nanomet
wavelength
use
opsi
micropl
reader
dynex
technolog
chantilli
va
quantit
extract
nr
absorb
valu
express
percentag
untreat
uninfect
control
took
maxim
dye
valu
obtain
convert
percentag
untreat
uninfect
control
cell
cytotox
dose
cc
viru
effect
dose
ec
repres
concentr
monolay
would
show
compound
cytotox
viral
cpe
respect
estim
regress
analysi
select
index
si
calcul
use
formula
si
cc
ec
vyr
assay
viral
titer
determin
endpoint
dilut
reed
muench
vyr
data
present
concentr
drug
reduc
viru
yield
log
unit
ec
base
linear
regress
analysi
si
valu
determin
cc
ec
femal
g
golden
syrian
hamster
charl
river
laboratori
willimant
ct
quarantin
day
prior
challeng
fed
standard
harlan
lab
block
tap
water
ad
libitum
anim
procedur
compli
usda
guidelin
conduct
aaalacaccredit
laboratori
anim
research
center
utah
state
univers
protocol
approv
utah
state
univers
anim
care
use
committe
determin
appropri
dose
subsequ
efficaci
studi
hamster
group
challeng
subcutan
sc
inject
ventral
right
side
abdomen
ml
inoculum
contain
pfu
rvfv
vari
dose
oral
po
evalu
efficaci
treatment
includ
mgkgday
ribavirin
posit
control
cmc
placebo
initi
h
postinfect
hpi
administ
twice
daili
day
five
anim
treatment
group
design
sacrific
day
infect
analysi
serum
liver
spleen
viral
titer
remain
anim
observ
day
morbid
mortal
shaminfect
normal
anim
includ
baselin
control
morbid
mortal
viru
titer
assay
serum
brain
liver
spleen
sampl
collect
two
moribund
anim
lateonset
encephalit
diseas
viral
titer
determin
histopatholog
sinc
hamster
begin
succumb
sc
rvfv
challeng
within
h
perform
followup
experi
wherein
treatment
effect
dose
initi
hpi
hamster
treatment
placebo
group
challeng
pfu
rvfv
dose
oral
twice
daili
day
mgkgday
ribavirin
mgkgday
placebo
start
hpi
four
anim
treatment
group
sacrif
day
infect
analysi
viral
titer
remain
anim
observ
day
morbid
mortal
shaminfect
normal
anim
includ
baselin
control
surviv
viru
titer
done
first
studi
serum
brain
liver
spleen
sampl
collect
sever
moribund
anim
lateonset
encephalit
diseas
viral
titer
determin
histopatholog
combin
antivir
effect
ribavirin
evalu
base
differ
protect
effect
observ
monotherapi
studi
hamster
treatment
group
placebo
group
challeng
sc
pfu
rvfv
ribavirin
placebo
dose
separ
combin
describ
tabl
start
hpi
four
anim
treatment
group
sacrif
day
infect
analysi
viral
titer
remain
anim
observ
day
morbid
mortal
shaminfect
control
includ
comparison
viru
titer
assay
use
infecti
cell
cultur
assay
previous
describ
briefli
specif
volum
tissu
homogen
serum
serial
dilut
ad
triplic
well
vero
cell
monolay
microtit
plate
viral
cpe
determin
day
plate
endpoint
calcul
describ
reed
muench
lower
limit
detect
viru
titer
log
cell
cultur
infecti
dose
ccid
ml
serum
log
ccid
g
tissu
respect
sever
moribund
anim
discov
day
dose
optim
postexposur
efficaci
studi
anim
sacrif
determin
serum
liver
spleen
brain
viru
titer
parallel
section
tissu
preserv
neutral
buffer
formalin
sent
utah
veterinari
diagnost
laboratori
logan
ut
blind
histopatholog
examin
analysi
board
certifi
veterinari
pathologist
mantelcox
logrank
test
use
analysi
kaplanmei
surviv
curv
oneway
analysi
varianc
anova
newmankeul
posttest
perform
compar
differ
viral
load
statist
evalu
done
use
prism
graphpad
softwar
la
jolla
ca
antivir
activ
first
evalu
cell
cultur
highli
virul
strain
rvfv
includ
ribavirin
comparison
cc
compound
inhibitori
activ
ec
rvfv
ribavirin
nr
cpe
reduct
assay
si
valu
respect
antivir
activ
confirm
measur
reduct
viru
yield
figur
endpoint
titrat
day
postinfect
cultur
supernat
ec
ribavirin
si
respect
consist
activ
detect
nr
uptak
assay
data
consist
previous
observ
activ
strain
rvfv
gowen
et
al
gowen
et
al
next
evalu
antivir
activ
hamster
challeng
strain
rvfv
initi
studi
assess
oral
treatment
mgkg
day
administ
start
h
post
sc
rvfv
infect
dose
twicedaili
durat
day
ribavirin
previous
shown
activ
rvfv
infect
peter
et
al
includ
comparison
shown
figur
treatment
mgkgday
efficaci
regimen
protect
challeng
anim
mortal
dose
significantli
better
ribavirin
treatment
mgkgday
result
surviv
anim
placebo
mgkgday
treatment
group
succumb
infect
day
slight
protect
effect
observ
dose
mgkgday
surviv
slight
delay
mean
day
death
approxim
day
effect
drug
treatment
reduc
viral
titer
evalu
day
hamster
infect
treat
parallel
observ
mortal
due
peracut
lethal
rvfv
challeng
hamster
one
anim
mgkgday
group
anim
lowdos
placebotr
group
expir
prior
time
sacrific
viral
titer
sera
liver
spleen
hamster
treat
mgkgday
significantli
reduc
compar
titer
hamster
treat
mg
kgday
p
figur
ribavirin
similar
effect
viral
titer
mgkgday
treatment
although
viru
detect
spleen
rvfvchalleng
hamster
treat
ribavirin
differ
signific
compar
highdos
group
figur
addit
day
viru
titer
data
two
anim
ribavirintr
group
found
moribund
state
day
postinfect
sacrif
analysi
serum
liver
spleen
brain
viru
titer
histopatholog
remark
viru
present
serum
liver
spleen
howev
approxim
log
ccid
g
tissu
present
brain
anim
figur
indic
anim
deterior
due
viru
replic
brain
associ
lateonset
enceph
corrobor
histopatholog
analysi
reveal
neutrophil
lymphocyt
meningoenceph
variabl
sever
brain
anim
figur
c
hamster
succumb
rvfv
challeng
within
hpi
next
evalu
efficaci
twicedaili
mgkgday
treatment
delay
h
post
sc
rvfv
infect
initi
experi
anim
receiv
highdos
treatment
initi
hpi
fare
significantli
better
compar
ribavirintr
anim
p
vs
surviv
surviv
acut
infect
ultim
succumb
lateonset
neurolog
diseas
figur
treatment
initi
hpi
also
demonstr
signific
protect
mortal
overal
surviv
anim
succumb
acut
system
infect
th
lateonset
encephalit
diseas
interestingli
ribavirin
treatment
delay
hpi
perform
similarli
treatment
initi
hpi
suggest
combin
therapi
start
late
one
day
challeng
may
effect
strategi
peracut
rvfv
hamster
infect
effect
treatment
reduc
viral
titer
day
postinfect
shown
figur
howev
mani
placebo
anim
ultim
expir
prior
sacrific
therebi
limit
statist
comparison
administ
hpi
effect
limit
viral
replic
demonstr
low
undetect
serum
liver
spleen
viral
titer
anim
hpi
group
titer
consider
higher
hpi
anim
remark
consid
anim
observ
group
surviv
challeng
suggest
even
slight
reduct
titer
delay
viral
replic
may
import
factor
favor
outcom
gener
trend
diminish
viral
titer
observ
hpi
anim
compar
placebo
anim
could
includ
analysi
consist
surviv
data
ribavirin
prevent
death
due
acut
infect
ribavirintr
anim
lowest
titer
hpi
treatment
group
figur
addit
day
viru
titer
data
four
anim
ribavirintr
group
one
anim
hpi
group
found
moribund
state
first
week
studi
day
anim
sacrif
determin
serum
liver
spleen
brain
viru
titer
histopatholog
consist
previou
experi
transit
system
hemorrhag
diseas
viral
enceph
diseas
mice
smith
et
al
viru
present
serum
spleen
one
anim
hpi
group
detect
viru
liver
log
ccid
g
data
shown
wherea
analysi
brain
tissu
reveal
viral
load
log
ccid
g
moribund
anim
figur
similar
observ
previou
studi
histopatholog
analysi
tissu
moribund
anim
suggest
deterior
anim
like
due
neutrophil
lymphocyt
meningoenceph
variabl
sever
figur
minim
lesion
hepat
present
anim
data
shown
collect
histopatholog
data
consist
notion
death
anim
beyond
day
primarili
due
rvfv
replic
brain
central
nervou
system
cn
infect
associ
diseas
like
caus
death
ribavirintr
anim
succumb
rvfv
challeng
although
ribavirin
effect
protect
hamster
acut
diseas
initi
hpi
succumb
latedevelop
brain
infect
diseas
consid
ribavirin
capac
provid
protect
lethal
due
acut
diseas
even
treatment
delay
hpi
encourag
efficaci
given
earli
infect
evalu
two
compound
combin
therapi
effort
provid
optim
protect
hamster
challeng
rvfv
sever
ribavirin
regimen
tabl
test
treatment
initi
hpi
ribavirin
treatment
cours
commonli
employ
load
dose
strategi
borio
et
al
mccormick
et
al
design
combin
studi
consider
mind
addit
lower
dose
ribavirin
also
evalu
address
concern
toxic
russmann
et
al
sinc
effect
reduc
dose
requir
would
greatli
benefit
patient
shown
figur
combin
treatment
result
signific
benefit
compar
either
drug
alon
treatment
effect
provid
protect
wherea
treatment
result
surviv
although
receiv
highest
effect
concentr
compound
treatment
tabl
appear
superior
ultim
survivor
notabl
combin
treatment
group
one
survivor
one
anim
ultim
succumb
day
individu
drug
treatment
group
expir
day
overal
combin
therapi
group
trend
toward
hamster
surviv
longer
ribavirin
mgkgday
monotherapi
effect
drug
combin
reduc
viral
titer
day
postinfect
shown
figur
consist
surviv
data
gener
trend
diminish
viral
titer
observ
ribavirin
combin
treatment
regimen
combin
treatment
appear
effect
reduc
viral
titer
serum
liver
spleen
compar
monotherapi
placebo
treat
group
significantli
better
ribavirin
monotherapi
collect
data
indic
combin
oral
treatment
ribavirin
significantli
enhanc
postexposur
efficaci
compar
monotherapi
either
drug
challeng
prevent
lateonset
enceph
still
problemat
treatment
postpon
h
rvfv
challeng
present
studi
demonstr
first
time
antivir
activ
pathogen
rvfv
infect
despit
similar
inhibitori
concentr
cell
cultur
experi
superior
ribavirin
term
overal
surviv
prevent
lateonset
cn
infect
rvfvinfect
hamster
although
detail
character
hamster
model
lack
similar
patholog
chang
describ
mice
report
liver
princip
target
sever
hepat
diseas
like
caus
death
acut
infect
delayedonset
encephalit
diseas
develop
first
week
niklasson
et
al
smith
et
al
hamster
gener
succumb
within
day
acut
diseas
wherea
mortal
mice
occur
first
day
ikegami
makino
speci
highli
suscept
rvfv
neither
reproduc
hemorrhag
fever
ocular
diseas
observ
human
case
rapid
progress
diseas
hamster
present
challeng
term
abbrevi
therapeut
window
howev
model
use
evalu
experiment
therapi
context
postexposur
intervent
demonstr
proofofconcept
robust
small
anim
model
possibl
dose
higher
mgkgday
may
achiev
complet
protect
lethal
rvfv
challeng
hamster
present
dose
mgkgday
equival
human
dose
mgkgday
base
bodi
surfac
area
convers
reaganshaw
et
al
phase
clinic
trial
evalu
antiinfluenza
drug
high
dose
arm
consist
mg
day
mg
day
assum
averag
weight
particip
kg
dosag
receiv
rang
mgkgday
respect
although
mgkgday
load
dose
subsequ
transit
mgkgday
evalu
rd
studi
therapeut
window
hamster
model
appear
extend
much
beyond
h
consid
excel
toler
hamster
ld
mgkgday
gowen
et
al
sever
rvfv
infect
may
worthwhil
explor
higher
daili
dose
administ
three
time
per
day
obtain
consist
therapeut
level
system
tissu
one
remark
find
studi
although
ribavirin
dramat
antivir
effect
rvfvinfect
hamster
effect
surviv
distinct
effect
term
protect
anim
acut
lateonset
cn
diseas
window
success
postexposur
intervent
limit
approxim
h
contrast
ribavirin
highli
effect
protect
anim
rapidli
overwhelm
effect
acut
infect
even
delay
treatment
hpi
wherea
slight
benefici
effect
could
observ
treatment
howev
almost
ribavirintr
anim
ultim
succumb
cn
infect
associ
diseas
absenc
detect
level
viru
serum
liver
spleen
sampl
find
consist
well
character
mous
rvfv
infect
model
wherein
lateonset
neuroinvas
enceph
describ
anim
succumb
latter
part
infect
smith
et
al
secondari
diseas
observ
hamster
could
serv
model
human
case
delayedonset
enceph
occur
week
month
acut
rvfv
infect
ikegami
makino
unclear
ribavirin
effect
control
viral
replic
abrog
diseas
initi
treatment
advanc
time
point
hpi
peracut
infect
ribavirin
may
achiev
higher
concentr
activ
primari
lymphat
tissu
viru
like
initi
replic
seed
blood
secondari
target
organ
includ
liver
specul
abl
prevent
cn
infect
narrow
window
intervent
complex
biodistribut
parent
compound
effici
intracellular
convers
activ
ribofuranosyl
triphosph
variou
cell
type
tissu
rate
elimin
probabl
influenc
observ
efficaci
shorter
window
effect
intervent
like
specif
target
rvfv
polymeras
directli
affect
viru
life
cycl
inhibit
viral
transcript
replic
wherea
ribavirin
multipl
mode
action
may
prevent
rvfv
lethal
later
act
cumul
effect
deplet
ribonucleotid
pool
leyssen
et
al
find
evalu
ribavirin
monotherapi
provid
rational
combin
two
antivir
goal
integr
benefici
aspect
independ
treatment
extend
therapeut
window
hpi
result
drug
combin
studi
indic
oral
treatment
ribavirin
significantli
enhanc
postexposur
efficaci
suggest
synergi
demonstr
protect
surviv
acut
hepat
lateonset
encephalit
diseas
would
otherwis
result
death
anim
treat
either
drug
alon
despit
success
challeng
prevent
lateonset
enceph
treatment
postpon
h
rvfv
infect
hamster
still
larg
unmet
interestingli
find
hint
highest
dose
combin
ribavirin
necessarili
optim
surviv
treatment
dose
one
drug
lower
result
improv
surviv
outcom
comprehens
drug
combin
matrix
would
need
clearli
demonstr
possibl
antagon
higher
dose
well
synergi
suboptim
dose
regimen
ribavirin
summari
postrvfv
exposur
treatment
hamster
within
hpi
ribavirin
combin
therapi
within
hpi
significantli
improv
surviv
outcom
reduc
viral
load
serum
tissu
fatal
case
rvf
sever
hemorrhag
diseas
manifest
typic
lead
death
within
day
onset
clinic
sign
ill
ikegami
makino
hamster
succumb
acut
phase
infect
within
day
display
initi
clinic
sign
lethargi
hunch
postur
ruffl
fur
difficult
extrapol
human
diseas
howev
consid
rapid
progress
lethal
rvfv
infect
diseas
model
hamster
data
present
certainli
encourag
view
failur
ribavirin
prevent
cn
infect
mice
challeng
upper
respiratori
tract
reed
et
al
futur
studi
investig
efficaci
aerosol
exposur
rodent
warrant
ultim
investig
new
drugen
efficaci
studi
nonhuman
primat
model
rvf
requir
advanc
compound
toward
clinic
evalu
efficaci
evalu
rvfv
challeng
hamster
model
treatment
significantli
reduc
mortal
rvfv
burden
ribavirin
protect
acut
diseas
lateonset
neurolog
complic
combin
ribavirin
therapi
may
offer
ad
protect
infect
hamster
challeng
sc
pfu
receiv
indic
dose
ribavirin
placebo
po
twice
daili
begin
h
postinfect
surviv
outcom
day
b
serum
c
liver
spleen
viru
titer
anim
infect
treat
parallel
shown
anim
mgkgday
placebo
treatment
group
one
hamster
mgkgday
treatment
group
succumb
prior
sacrific
uniqu
symbol
treatment
group
repres
valu
anim
bd
percent
surviv
p
p
compar
placebo
b
p
compar
anim
treat
ribavirin
viral
titer
p
p
compar
anim
treat
mgkgday
hamster
treat
describ
figur
two
anim
ribavirintr
group
found
moribund
day
postinfect
sacrif
analysi
serum
liver
spleen
brain
viru
titer
histopatholog
analysi
viral
titer
moribund
rvfvinfect
hamster
treat
ribavirin
histopatholog
find
cerebrum
display
b
multifoc
neuron
necrosi
neuronophagia
c
neuropil
necrosi
h
e
stain
bar
hamster
treat
mgkgday
ribavirin
mgkgday
placebo
twicedaili
po
day
begin
h
postinfect
hpi
percent
surviv
day
b
serum
c
liver
spleen
viru
titer
shown
five
anim
vari
placebo
group
one
anim
hpi
group
succumb
prior
sacrific
uniqu
symbol
treatment
group
repres
valu
anim
bd
p
p
compar
respect
placebo
group
b
p
c
p
compar
anim
treat
ribavirin
hamster
treat
describ
figur
five
anim
discov
moribund
euthan
indic
day
postinfect
analysi
viru
titer
histopatholog
brain
viral
titer
moribund
rvfvinfect
hamster
treat
blue
symbol
ribavirin
red
symbol
histopatholog
analysi
cerebrum
display
b
perivascular
mix
inflammatori
cell
infiltr
c
neutrophil
choroid
ventricul
neutrophil
mening
e
neuropil
vascul
hemorrhag
h
e
stain
bar
tabl
detail
descript
treatment
regimen
percent
surviv
day
b
serum
c
liver
spleen
viru
titer
shown
one
anim
monotherapi
placebotr
group
succumb
prior
sacrific
day
uniqu
symbol
treatment
group
repres
valu
anim
bd
p
p
p
compar
placebotr
anim
p
b
p
c
p
compar
anim
receiv
monotherapi
x
p
z
p
compar
hamster
treat
ribavirin
h
high
dose
l
low
dose
ld
load
dose
postexposur
plu
ribavirin
combin
treatment
regimen
highlow
dose
dosag
mgkgday
b
